Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia.

Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia. Abstract Text:

Mark E Rupp,H Preston Holley,Jon Lutz,Peter V Dicpinigaitis,Christopher W Woods,Donald P Levine,Naomi Veney,Vance G Fowler,Mark E Rupp,H Preston Holley,Jon Lutz,Peter V Dicpinigaitis,Christopher W Woods,Donald P Levine,Naomi Veney,Vance G Fowler,

New treatment modalities are needed for the treatment of infections due to multidrug-resistant Staphylococcus aureus. S. aureus capsular polysaccharide immune globulin (Altastaph) is a polyclonal immune globulin preparation that is being developed as adjunctive therapy for persons with S. aureus infections complicated by bacteremia. In a phase II, multicenter, randomized, double-blind, placebo-controlled trial, 40 subjects with documented S. aureus bacteremia received standard therapy plus either Altastaph at 200 mg/kg of body weight in each of two infusions 24 h apart or placebo. During the 42-day observation period, antibody pharmacokinetics and safety were the primary characteristics studied. Information regarding the resolution of bacteremia and fever was also analyzed. Anti-type-5 and anti-type-8 capsular antibody levels peaked after the second infusion at 550 mug/ml and 419 mug/ml, respectively, and remained above 100 mug/ml at day 28. A total of 316 adverse events were noted in 39 of 40 subjects. Infusion-related adverse events in Altastaph recipients were infrequent and similar to those among recipients of commercial intravenously administered immunoglobulin G products. Five of 21 (23%) subjects in the Altastaph group died, whereas 2 of 18 (11%) subjects in the placebo group died (P = 0.42). Compared to the control patients, the Altastaph recipients had a shorter median time to the resolution of fever (2 days and 7 days, respectively; P = 0.09) and a shorter length of hospital stay (9 days and 14 days, respectively; P = 0.03). However, these findings are exploratory, and there were few differences in the other variables measured. High levels of opsonizing antibodies were maintained for the initial 4 weeks. Although the study was not powered to show efficacy, these preliminary findings and safety profile suggest that Altastaph may be an effective adjunct to antibiotics and warrants further investigation (ClinicalTrials.gov number NCT00063089).

Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia. Publishing Authors By Initials

ME Rupp,HP Holley,J Lutz,PV Dicpinigaitis,CW Woods,DP Levine,N Veney,VG Fowler,ME Rupp,HP Holley,J Lutz,PV Dicpinigaitis,CW Woods,DP Levine,N Veney,VG Fowler,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Antimicrobial agents and chemotherapy

VOLUME: 51

Page Numbers: 4249-54

Journal Abbreviation: Antimicrob. Agents Chemother.

ISSN: 0066-4804

DAY: 24

MONTH: 09

YEAR: 2007

Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 315061

Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia.

AFFILIATION: Division of Infectious Diseases, University of Nebraska Medical Center, 984031 Nebraska Medical Center, Omaha, NE 68198-4031. merupp@unmc.edu.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Antimicrob Agents Chemother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia Related Publications

• A bold new beginning for midwifery in Afghanistan.
• A descriptive analysis of Emergency Medical Service Systems participating in the Resuscitation Outcomes Consortium (ROC) network.
• A fatality from sevoflurane abuse.
• A molecular characterization of spontaneous frameshift mutagenesis within the trpA gene of Escherichia coli.
• Artificial breeding of non-domestic animals Watson, P.F. (ed.): Symposium 43, of the Zoological Society of London. London & N.Y., Academic Press. 1978. Price: 16 pounds (British).
• Chronic ingestion of (3R,3'R,6'R)-lutein and (3R,3'R)-zeaxanthin in the female rhesus macaque.
• Contentious issue of funding and the pharmaceutical industry--should service user groups take the big pharma shilling, and and what are the costs if they do?
• Distribution of phencyclidine into vitreous humor.
• Double-bridged Flap Procedure for Nonmarginal, Full-thickness, Upper Eyelid Reconstruction.
• Editorial comment on: extracorporeal magnetic stimulation is of limited clinical benefit to women with idiopathic detrusor overactivity: a randomized sham controlled trial.
• Hypoxia inducible factor-1 modulates hemin-induced IL-8 secretion in microvascular endothelium.
• Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial.
• Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake.
• Measuring forelimb force control and movement in Fischer 344/Brown Norway rats: effects of age and lorazepam.
• Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia.
• Predicted light scattering from particles observed in human age-related nuclear cataracts using mie scattering theory.
• Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia.
• Role of macromolecular assembly of enamel matrix proteins in enamel formation.
• Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial alpha7 nicotinic cholinergic agonist drug.
• Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec).
• The application of cognitive-behavioral therapy for psychosis in clinical and research settings.
• The association between traumatic experience, paranoia and hallucinations: a test of the predictions of psychological models.
• The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action.
• The influence of crank length and cadence on mechanical efficiency in hand cycling.
• The pharmacology of the cannabinoid system--a question of efficacy and selectivity.
• Tmod3 regulates polarized epithelial cell morphology.
• Tropomodulin 3 binds to actin monomers.
• Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.
• Visual influences on perception of speech and nonspeech vocal-tract events.
• Who's stigmatising whom?